In vitro generation of allospecific human CD8+ T cells of Tc1 and Tc2 phenotype

Blood

Volumn 90, Issue 5, 1997, Pages 2089-2096

  Halverson, David C ^b   Schwartz, Gretchen N ^b   Carter, Charles ^b   Gress, Ronald E ^b   Fowler, Daniel H ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ALLOGENEIC RESTRICTION; ARTICLE; CYTOLYSIS; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

EID: 0030964547     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.5.2089     Document Type: Article

References (36)

1. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136:2348, 1986
2. + T cells secreting Th1 or Th2 cytokines. Immunity 2:271, 1995
3. Croft M, Carter L, Swain SL, Dutton RW: Generation of polarized antigen-specific CD8 effector populations: Reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 180:1715, 1994
4. + T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 179:589, 1994
5. + Tc1 and Tc2 populations in GVL and GVHD. J Immunol 157:4811, 1996
6. + T cells fail to induce experimental acute graft-versus-host disease. J Immunol 155:585, 1995
7. Truitt RL, Johnson BD: Principles of graft-vs.-leukemia reactivity. Biol Blood Marrow Transplant 1:61, 1995
8. Abhyankar S, Gilliland DG, Ferrara JL: Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens. Transplantation 56:1518, 1993
9. Romagnani S: Lymphokine production by human T cells in disease states. Annu Rev Immunol 12:227, 1994
10. Yamamuru M, Uyemura K, Deans RJ, Weinberg K, Rea TH, Bloom BR, Modlin RL: Defining protective responses to pathogens: Cytokine profiles in leprosy lesions. Science 254:277, 1991
11. Zhang M, Gately MK, Wang E, Gong J, Wolf SF, Lu S, Modlin RL, Barnes PF: Interleukin 12 at the site of disease in tuberculosis. J Clin Invest 93:1733, 1994
12. + type 2 T cell subsets in human leishmaniasis have distinct T cell receptor repertoires. J Immunol 151:7095, 1993
13. Clerici M, Shearer GM: A TH1 → TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 14:107, 1993
14. Demeure CE, Wu CY, Shu U, Schneider PV, Heusser C, Yssel H, Delespesse G: In vitro maturation of human neonatal CD4 T lymphocytes. II. Cytokines present at priming modulate the development of lymphokine production. J Immunol 152:4775, 1994
15. Byun DG, Demeure CE, Yang LP, Shu U, Ishihara H, Vezzio N, Gately MK, Delespesse G: In vitro maturation of neonatal human CD8 T lymphocytes into IL-4-and IL-5-producing cells. J Immunol 153:4862, 1994
16. Quinones RR, Gutierrez RH, Dinndorf PA, Gress RE, Ney AB, Taylor B, Karandish S, Carter CS, Luban NL, Reaman GH: Extended-cycle elutriation to adjust T-cell content in HLA-disparate bone marrow transplantation. Blood 82:307, 1993
17. Wunderlich J, Shearer G: Induction and measurement of cytotoxic T lymphocyte activity, in Coligan JE, Kruisbeek AM, Marguilies DH, Shevach EM, Strober W (eds): Current Protocols in Immunology. New York, NY, Wiley, 1992, p 3.11.4
18. Titus JA, Garrido MA, Hecht TT, Winkler DF, Wunderlich JR, Segal DM: Human T cells targeted with anti-T3 cross-linked to antitumor antibody prevent tumor growth in nude mice. J Immunol 138:4018, 1987
19. Rouvier E, Luciani MF, Goldstein P: Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med 177:195, 1993
20. - cells that make TH2 cytokines and help B cells. Science 260:1802, 1993
21. Carter LL, Dutton RW: Relative perform-and Fas-mediated lysis in T1 and T2 CD8 effector populations. J Immunol 155:1028, 1995
22. +, Tc1/Tc2 populations in murine GVL: Type I cells generate GVL, type II cells abrogate GVL. Biol Blood Marrow Transplant 2:118, 1996
23. Sad S, Mosmann TR: Single IL-2-secreting precursor CD4 T cells can develop into either Th1 or Th2 cytokine secretion phenotype. J Immunol 153:3514, 1994
24. Nagelkerken L, Gollob KJ, Tielemans M, Coffman RL: Role of transforming growth factor-beta in the preferential induction of T helper cells of type 1 by staphylococcal enterotoxin B. Eur J Immunol 23:2306, 1993
25. Sandstrom PA, Mannie MD, Buttke TM: Inhibition of activation-induced death in T cell hybridomas by thiol antioxidants: Oxidative stress as a mediator of apoptosis. J Leukoc Biol 55:221, 1994
26. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ: Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75:241, 1993
27. Chiba T, Takahashi S, Sato N, Ishii S, Kikuchi K: Fas-mediated apoptosis is modulated by intracellular glutathione in human T cells. Eur J Immunol 26:1164, 1996
28. Londei M, Verhoet A, Hawrylowicz C, Groves J, De Berardinis P, Feldmann M: Interleukin 7 is a growth factor for mature human T cells. Eur J Immunol 20:425, 1990
29. Kos FJ, Mullbacher A: IL-2-independent activity of IL-7 in the generation of secondary antigen-specific cytotoxic T cell responses in vitro. J Immunol 150:387, 1993
30. Lynch DH, Miller RE: Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo. J Exp Med 179:31, 1994
31. Rich BE, Campos-Torres J, Tepper RI, Moreadith RW, Leder P: Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J Exp Med 177:305, 1993
32. Bhatia SK, Tygrett LT, Grabstein KH, Waldschmidt TJ: The effect of in vivo IL-7 deprivation on T cell maturation. J Exp Med 181:1399, 1995
33. Henkart PA: Lymphocyte-mediated cytotoxicity: Two pathways and multiple effector molecules. Immunity 1:343, 1994
34. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H, Golstein P: Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528, 1994
35. Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J: Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 183:657, 1996
36. Rensing-Ehl A, Frei K, Flury R, Matiba B, Mariani SM, Weller M, Aebischer P, Krammer PH, Fontana A: Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 25:2253, 1995